Skip to main content

Advertisement

Log in

One-year results after intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion

  • Retinal Disorders
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Background

To investigate the long-term effectiveness of intravitreal bevacizumab treatment in eyes with perfused macular edema due to branch retinal vein occlusion (BRVO).

Methods

In this prospective interventional case series, 23 consecutive, previously untreated eyes with perfused macular edema were treated with intravitreal bevacizumab (1.25 mg) injections and followed for 1 year. The main outcome measures were visual acuity (VA) and central retinal thickness (CRT). In addition, VA data were adapted to the non-logarithmic VA charts used in the previously published grid laser photocoagulation BRVO Study.

Results

The median VA gained 3.0 lines from baseline at 48 weeks. This was accompanied by a significant decrease of 39% of the median CRT. The mean number of re-injections was 1.6 during the first 6 months of follow-up and only 0.8 during the subsequent 6 months. In 65% of the cases, adapted VA data showed a gain of 1 or more lines and no eye lost more than 1 line.

Conclusions

Repetitive intravitreal bevacizumab injections result in a significant long-term improvement of VA and CRT. The number of re-injections necessary to maintain this effect declined over time. However, the treatment seems to be only slightly better than grid laser photocoagulation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. The Branch Vein Occlusion Study Group (1984) Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol 98:271–282

    Google Scholar 

  2. Mandelcorn MS, Nrusimhadevara RK (2004) Internal limiting membrane peeling for decompression of macular edema in retinal vein occlusion: a report of 14 cases. Retina 24:348–355. doi:10.1097/00006982-200406000-00002

    Article  PubMed  Google Scholar 

  3. Mester U, Dillinger P (2002) Vitrectomy with arteriovenous decompression and internal limiting membrane dissection in branch retinal vein occlusion. Retina 22:740–746. doi:10.1097/00006982-200212000-00009

    Article  PubMed  Google Scholar 

  4. Fekrat S, Goldberg MF, Finkelstein D (1998) Laser-induced chorioretinal venous anastomosis for nonischemic central or branch retinal vein occlusion. Arch Ophthalmol 116:43–52

    PubMed  CAS  Google Scholar 

  5. Weiss JN, Bynoe LA (2001) Injection of tissue plasminogen activator into a branch retinal vein in eyes with central retinal vein occlusion. Ophthalmology 108:2249–2257. doi:10.1016/S0161-6420(01)00875-2

    Article  PubMed  CAS  Google Scholar 

  6. Singh RP, Margolis R, Kaiser PK (2007) Cystoid puncture for chronic cystoid macular oedema. Br J Ophthalmol 91:1062–1064. doi:10.1136/bjo.2006.101790

    Article  PubMed  Google Scholar 

  7. Cekiç O, Chang S, Tseng JJ, Barile GR, DelPriore LV, Weissman H et al (2005) Intravitreal triamcinolone injection for treatment of macular edema secondary to branch retinal vein occlusion. Retina 25:851–855. doi:10.1097/00006982-200510000-00006

    Article  PubMed  Google Scholar 

  8. Jaissle GB, Ziemssen F, Petermeier K, Szurman P, Ladewig M, Gelisken F et al (2006) Bevacizumab for treatment of macular edema secondary to retinal vein occlusion. Ophthalmologe 103:471–475. doi:10.1007/s00347-006-1355-2

    Article  PubMed  CAS  Google Scholar 

  9. Stahl A, Agostini H, Hansen LL, Feltgen N (2007) Bevacizumab in retinal vein occlusion-results of a prospective case series. Graefes Arch Clin Exp Ophthalmol 245:1429–1436. doi:10.1007/s00417-007-0569-6

    Article  PubMed  CAS  Google Scholar 

  10. Pai SA, Shetty R, Vijayan PB, Venkatasubramaniam G, Yadav NK, Shetty BK et al (2007) Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion. Am J Ophthalmol 143:601–606. doi:10.1016/j.ajo.2006.12.037

    Article  PubMed  CAS  Google Scholar 

  11. Rabena MD, Pieramici DJ, Castellarin AA, Nasir MA, Avery RL (2007) Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina 27:419–425. doi:10.1097/IAE.0b013e318030e77e

    Article  PubMed  Google Scholar 

  12. Kreutzer TC, Alge CS, Wolf AH, Kook D, Burger J, Strauss R et al (2008) Intravitreal bevacizumab for the treatment of macular edema secondary to branch retinal vein occlusion. Br J Ophthalmol 92:351–355. doi:10.1136/bjo.2007.123513

    Article  PubMed  CAS  Google Scholar 

  13. Kriechbaum K, Michels S, Prager F, Georgopoulos M, Funk M, Geitzenauer W et al (2008) Intravitreal Avastin for macular edmema secondary to retinal vein occlusion - a prospective study. Br J Ophthalmol 92:518–522. doi:10.1136/bjo.2007.127282

    Article  PubMed  CAS  Google Scholar 

  14. Wu L, Arevalo JF, Roca JA, Maia M, Berrocal MH, Rodriguez FJ et al (2008) Pan-American Collaborative Retina Study Group (PACORES). Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up. Retina 28:212–219

    Article  PubMed  CAS  Google Scholar 

  15. Jaissle GB, Karl I, Bartz-Schmidt KU (2008) Einwilligung und Besonderheiten der Aufklärung im Off-Label-Bereich. In: Bartz-Schmidt KU, Ziemssen F (Eds) Intravitreale Pharmakotherapie. Moderne Medikamente und ihre Anwendung am Auge. Schattauer, Stuttgart, pp 25–29

    Google Scholar 

  16. Jaissle GB, Szurman P, Bartz-Schmidt KU, German Retina Society German Society of Ophthalmology; German Professional Association of Ophthalmologists (2005) Recommendation for the implementation of intravitreal injections-statement of the German Retina Society, the German Society of Ophthalmology (DOG) and the German Professional Association of Ophthalmologists (BVA). Klin Monatsbl Augenheilkd 222:390–395. doi:10.1055/s-2005-858231

    Article  PubMed  CAS  Google Scholar 

  17. Sadda SR, Wu Z, Walsh AC, Richine L, Dougall J, Cortez R et al (2006) Errors in retinal thickness measurements obtained by optical coherence tomography. Ophthalmology 113:285–293. doi:10.1016/j.ophtha.2005.10.005

    Article  PubMed  Google Scholar 

  18. Bolz M, Ritter M, Polak K, Ahlers C, Hirn C, Prünte C et al (2008) The role of Stratus OCT in anti-VEGF therapy: Qualitative and quantitative assessment of neovascular AMD. Ophthalmologe [Epub ahead of print]

Download references

Acknowledgement

The authors thank Dr. Barbara Wallenfels-Thilo for excellent editorial assistance.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Gesine B. Jaissle.

Additional information

Gesine B Jaissle, Martin Leitritz: These authors contributed equally to the work.

The study has been supported by the German Ophthalmological Society (DOG).

The authors have no financial disclosures. The authors declare no conflicts of interest.

The authors have full control of all primary data, and they agree to allow Graefe’s Archive for Clinical and Experimental Ophthalmology to review their data if requested.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jaissle, G.B., Leitritz, M., Gelisken, F. et al. One-year results after intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 247, 27–33 (2009). https://doi.org/10.1007/s00417-008-0916-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-008-0916-2

Keywords

Navigation